To prevent relapse, BCL2 inhibitor ABT199 (venetoclax), in combination with ER antagonist (fulvestrant) and palbociclib, was administered to ER+ breast cancer cell lines, patient-derived organoid (PDO), PDX and syngeneic immunocompetent mouse models. Here, ESR1 is linked to breast carcinoma.